Rapid Micro Biosystems (RPID) Cost of Revenue (2020 - 2026)

Rapid Micro Biosystems has disclosed Cost of Revenue across 7 years of filings, most recently posting $6.8 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 2.08% year-over-year to $6.8 million; the TTM figure through Jun 2026 stood at $30.1 million (up 21.7% YoY), while the FY2025 annual figure was $26.0 million, up 23.47% from the prior year.
• Cost of Revenue came in at $6.8 million for Q2 2026 at Rapid Micro Biosystems, down from $7.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.1 million in Q4 2025 to a low of $3.2 million in Q2 2022.
• Average Cost of Revenue over 5 years is $5.7 million, with a median of $5.4 million recorded in 2024.
• Year-over-year, Cost of Revenue plunged 46.9% in 2022 and surged 78.68% in 2025.
• Over 5 years, Cost of Revenue stood at $5.3 million in 2022, then declined by 10.61% to $4.7 million in 2023, then climbed by 19.96% to $5.6 million in 2024, then surged by 78.68% to $10.1 million in 2025, then sank by 32.07% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $6.8 million in Q2 2026, $7.6 million in Q1 2026, and $10.1 million in Q4 2025.